CVM Quote, Financials, Valuation and Earnings

Actinium Pharmaceuticals has a net margin of -- compared to CEL-SCI's net margin of -11511.11%. CEL-SCI's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 3245.88%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 278.79%. Given that CEL-SCI has higher upside potential than Actinium Pharmaceuticals, analysts believe CEL-SCI is more attractive than Actinium Pharmaceuticals.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.274, suggesting its less volatile than the S&P 500 by 127.35%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. CEL-SCI's net income of -$7.1M is higher than Actinium Pharmaceuticals's net income of -$11.6M. Notably, CEL-SCI's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to CEL-SCI's net margin of --. CEL-SCI's return on equity of -- beat Perspective Therapeutics's return on equity of --.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 3245.88%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 602.09%. Given that CEL-SCI has higher upside potential than Perspective Therapeutics, analysts believe CEL-SCI is more attractive than Perspective Therapeutics.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. CEL-SCI's net income of -$7.1M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 13.27x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to CEL-SCI's net margin of -711.67%. CEL-SCI's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 3245.88%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1277.04%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.449, suggesting its more volatile than the S&P 500 by 44.948%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. CEL-SCI's net income of -$7.1M is lower than IGC Pharma's net income of -$1.8M. Notably, CEL-SCI's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 16.55x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

OS Therapies has a net margin of -- compared to CEL-SCI's net margin of --. CEL-SCI's return on equity of -- beat OS Therapies's return on equity of --.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 3245.88%. On the other hand OS Therapies has an analysts' consensus of $13.50 which suggests that it could grow by 930.53%. Given that CEL-SCI has higher upside potential than OS Therapies, analysts believe CEL-SCI is more attractive than OS Therapies.

CEL-SCI has a beta of 0.951, which suggesting that the stock is 4.939% less volatile than S&P 500. In comparison OS Therapies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OS Therapies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. OS Therapies pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than OS Therapies quarterly revenues of --. CEL-SCI's net income of -$7.1M is lower than OS Therapies's net income of -$2.9M. Notably, CEL-SCI's price-to-earnings ratio is -- while OS Therapies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus -- for OS Therapies. Usually stocks with elevated PS ratios are considered overvalued.